NCT01949870View on ClinicalTrials.gov

Selumetinib (AZD6244, ARRY-142886) J-BTC Phase 1 Study

PHASE1TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Inoperable Locally Advanced or Metastatic Biliary Tract Cancer
Interventions
DRUG

Cisplatin

day1 and day8 at each cycle

DRUG

Gemcitabine

day1 and day8 at each cycle

DRUG

Selumetinib

25mg/day, 50mg/day and 75mg/day

Trial Locations (2)

Unknown

AZD6244 PhI Japanese Gem/, Kashiwa Shi

AZD6244 PhI Japanese Gem/, Chuo Ku

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY